Effective January 1, 2027, MedBen Rx will add Omlyclo, a biosimilar to Xolair, to the formulary for clients participating in its biosimilar program. Omlyclo is used to treat certain patients with allergic asthma, nasal polyps, or chronic hives and to help reduce the risk of severe reactions from accidental food exposure. The addition builds on a program that has saved clients up to 95% on select biosimilars over the past four years.
MedBen Rx will work directly with prescribing providers to help members make the switch. With more potential U.S. biosimilar launches expected in 2027, MedBen Rx will continue to evaluate new options and add selected products to the program.
If you have questions about the biosimilar program or what the addition of Omlyclo means for your plan, please contact your MedBen Account Management team.
